Efficacy and safety of leuprorelin 3-month depot (11.25 mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study
Author:
Huang Siqi1, Zhang Lina1, Gao Chenchen1, Ou Hui1, Hou Lele1ORCID, Liu Zulin1, Wang Dilong1, Xu Yingying1, Liang Liyang1, Meng Zhe1
Affiliation:
1. Department of Pediatrics, Sun Yat-sen Memorial Hospital , Sun Yat-sen University , Guangzhou , China
Abstract
Abstract
Objectives
This study aimed to evaluate the efficacy and safety of 3-month leuprorelin acetate (3-month LA, 11.25 mg) for the treatment of idiopathic central precocious puberty (ICPP) in Chinese girls.
Methods
We conducted a single-center retrospective study in China on 28 girls with ICPP who received at least one year of 3-month LA treatment. Data from anthropometry, biochemistry, bone age (BA), and pelvic ultrasonography were assessed before and every 6 months during medication.
Results
At CPP diagnosis, the mean chronological age (CA) was 7.8±0.8 years, with bone age advancement (BA–CA) of 1.5±0.8 years. After treatment initiation, growth velocity decreased significantly from 8.5±1.6 cm/year to 5.8±1.1 cm/year at month 12 (p<0.001). GnRH-stimulated peak LH ≤3IU/L, the primary efficacy criterion, was observed in 27 out of 28 (96.4 %) children at month 3. Basal estradiol <20 pg/mL was achieved by all 28 girls (100 %) at month 6 and remained stable at month 12. Basal follicle-stimulating hormone (FSH) decreased from 4.1±3.5 to 1.7±0.9 (p<0.001), and basal LH was also significantly reduced from 3.3±6.5 to 0.7±0.8 (p=0.035) at month 12. The mean predicted adult height (PAH) at treatment initiation was 152.7±5.8 cm, it increased significantly to 157.5±5.5 cm (p=0.007) after one-year treatment. Pubertal development was slowed in most patients, and in some cases, it was even reversed. Only one patient (3.6 %) reported local intolerance.
Conclusions
Three-month leuprorelin acetate is a safe and effective treatment for suppressing the pituitary–gonadal axis and restoring impaired adult height in Chinese girls.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference27 articles.
1. Latronico, AC, Brito, VN, Carel, JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016;4:265–74. https://doi.org/10.1016/s2213-8587(15)00380-0. 2. Carel, JC, Léger, J. Clinical practice. Precocious puberty. N Engl J Med 2008;358:2366–77. https://doi.org/10.1056/nejmcp0800459. 3. Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, K, Popovic, J, Houk, C, et al.. Use of gonadotropinreleasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357–72. https://doi.org/10.1159/000501336. 4. Carel, JC, Lahlou, N, Jaramillo, O, Montauban, V, Teinturier, C, Colle, M, et al.. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111–16. https://doi.org/10.1210/jc.2001-020243. 5. Lee, PA, Klein, K, Mauras, N, Neely, EK, Bloch, CA, Larsen, L, et al.. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572–80. https://doi.org/10.1210/jc.2011-2704.
|
|